vs
FULTON FINANCIAL CORP（FULT）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是FULTON FINANCIAL CORP的1.6倍（$540.7M vs $336.2M），FULTON FINANCIAL CORP净利率更高（28.2% vs -2.9%，领先31.1%），FULTON FINANCIAL CORP同比增速更快（4.2% vs -14.1%），过去两年FULTON FINANCIAL CORP的营收复合增速更高（0.2% vs -2.3%）
富尔顿金融公司是美国的区域性金融服务控股企业，总部位于宾夕法尼亚州兰开斯特市，主要为当地及周边区域提供多元化的金融相关服务，在区域金融市场拥有稳定的业务布局。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
FULT vs ICUI — 直观对比
营收规模更大
ICUI
是对方的1.6倍
$336.2M
营收增速更快
FULT
高出18.3%
-14.1%
净利率更高
FULT
高出31.1%
-2.9%
两年增速更快
FULT
近两年复合增速
-2.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $336.2M | $540.7M |
| 净利润 | $94.8M | $-15.7M |
| 毛利率 | — | 37.5% |
| 营业利润率 | — | 1.0% |
| 净利率 | 28.2% | -2.9% |
| 营收同比 | 4.2% | -14.1% |
| 净利润同比 | 1.9% | 34.0% |
| 每股收益（稀释后） | $0.55 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FULTICUI
| Q1 26 | $336.2M | — | ||
| Q4 25 | $336.0M | $540.7M | ||
| Q3 25 | $334.6M | $537.0M | ||
| Q2 25 | $324.1M | $548.9M | ||
| Q1 25 | $318.4M | $604.7M | ||
| Q4 24 | $319.6M | $629.8M | ||
| Q3 24 | $317.7M | $589.1M | ||
| Q2 24 | $334.7M | $596.5M |
净利润FULTICUI
| Q1 26 | $94.8M | — | ||
| Q4 25 | $99.0M | $-15.7M | ||
| Q3 25 | $100.5M | $-3.4M | ||
| Q2 25 | $99.2M | $35.3M | ||
| Q1 25 | $93.0M | $-15.5M | ||
| Q4 24 | $68.6M | $-23.8M | ||
| Q3 24 | $63.2M | $-33.0M | ||
| Q2 24 | $95.0M | $-21.4M |
毛利率FULTICUI
| Q1 26 | — | — | ||
| Q4 25 | — | 37.5% | ||
| Q3 25 | — | 37.4% | ||
| Q2 25 | — | 37.9% | ||
| Q1 25 | — | 34.7% | ||
| Q4 24 | — | 36.1% | ||
| Q3 24 | — | 34.8% | ||
| Q2 24 | — | 34.8% |
营业利润率FULTICUI
| Q1 26 | — | — | ||
| Q4 25 | 35.7% | 1.0% | ||
| Q3 25 | 38.2% | 2.6% | ||
| Q2 25 | 37.8% | 1.9% | ||
| Q1 25 | 36.1% | 2.1% | ||
| Q4 24 | 27.0% | 6.0% | ||
| Q3 24 | 25.1% | 1.4% | ||
| Q2 24 | 30.8% | 1.3% |
净利率FULTICUI
| Q1 26 | 28.2% | — | ||
| Q4 25 | 29.5% | -2.9% | ||
| Q3 25 | 30.0% | -0.6% | ||
| Q2 25 | 30.6% | 6.4% | ||
| Q1 25 | 29.2% | -2.6% | ||
| Q4 24 | 21.5% | -3.8% | ||
| Q3 24 | 19.9% | -5.6% | ||
| Q2 24 | 28.4% | -3.6% |
每股收益（稀释后）FULTICUI
| Q1 26 | $0.55 | — | ||
| Q4 25 | $0.53 | $-0.63 | ||
| Q3 25 | $0.53 | $-0.14 | ||
| Q2 25 | $0.53 | $1.43 | ||
| Q1 25 | $0.49 | $-0.63 | ||
| Q4 24 | $0.36 | $-0.97 | ||
| Q3 24 | $0.33 | $-1.35 | ||
| Q2 24 | $0.52 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.5B | $2.1B |
| 总资产 | $32.2B | $4.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FULTICUI
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $308.6M | ||
| Q3 24 | — | $312.5M | ||
| Q2 24 | — | $302.6M |
股东权益FULTICUI
| Q1 26 | $3.5B | — | ||
| Q4 25 | $3.5B | $2.1B | ||
| Q3 25 | $3.4B | $2.1B | ||
| Q2 25 | $3.3B | $2.1B | ||
| Q1 25 | $3.3B | $2.0B | ||
| Q4 24 | $3.2B | $2.0B | ||
| Q3 24 | $3.2B | $2.0B | ||
| Q2 24 | $3.1B | $2.0B |
总资产FULTICUI
| Q1 26 | $32.2B | — | ||
| Q4 25 | $32.1B | $4.1B | ||
| Q3 25 | $32.0B | $4.1B | ||
| Q2 25 | $32.0B | $4.1B | ||
| Q1 25 | $32.1B | $4.2B | ||
| Q4 24 | $32.1B | $4.2B | ||
| Q3 24 | $32.2B | $4.3B | ||
| Q2 24 | $31.8B | $4.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $60.6M |
| 自由现金流经营现金流 - 资本支出 | — | $36.0M |
| 自由现金流率自由现金流/营收 | — | 6.6% |
| 资本支出强度资本支出/营收 | — | 4.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $91.8M |
8季度趋势，按日历期对齐
经营现金流FULTICUI
| Q1 26 | — | — | ||
| Q4 25 | $304.5M | $60.6M | ||
| Q3 25 | $116.1M | $56.7M | ||
| Q2 25 | $91.7M | $11.2M | ||
| Q1 25 | $703.0K | $51.3M | ||
| Q4 24 | $416.6M | $40.2M | ||
| Q3 24 | $-22.0M | $36.1M | ||
| Q2 24 | $157.8M | $82.0M |
自由现金流FULTICUI
| Q1 26 | — | — | ||
| Q4 25 | — | $36.0M | ||
| Q3 25 | — | $27.6M | ||
| Q2 25 | — | $-8.5M | ||
| Q1 25 | — | $36.7M | ||
| Q4 24 | — | $16.1M | ||
| Q3 24 | — | $16.2M | ||
| Q2 24 | — | $62.5M |
自由现金流率FULTICUI
| Q1 26 | — | — | ||
| Q4 25 | — | 6.6% | ||
| Q3 25 | — | 5.1% | ||
| Q2 25 | — | -1.5% | ||
| Q1 25 | — | 6.1% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 10.5% |
资本支出强度FULTICUI
| Q1 26 | — | — | ||
| Q4 25 | — | 4.6% | ||
| Q3 25 | — | 5.4% | ||
| Q2 25 | — | 3.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | — | 3.4% | ||
| Q2 24 | — | 3.3% |
现金转化率FULTICUI
| Q1 26 | — | — | ||
| Q4 25 | 3.08× | — | ||
| Q3 25 | 1.16× | — | ||
| Q2 25 | 0.92× | 0.32× | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 6.07× | — | ||
| Q3 24 | -0.35× | — | ||
| Q2 24 | 1.66× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FULT
暂无分部数据
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
